Quote:

---

What are we missing here guys / gals ?????

---

Cash. CYDY is missing cash to pursue the science at a rapid pace. And cash on the balance sheet to assure shareholders there won't be another warrant-backed raise.

CYDY management's strategy appears to be to hold out for the best possible deal and to avoid selling all or part of any indication for less than "full value" (however you define that).

It remains to be seen whether that is an optimal strategy or whether CYDY and shareholders would have been better off to parcel out leronlimab geographically (e.g., license leronlimab in Japan for upfront $$ and small royalty) or by indication (e.g., the HIV deal that is now "on pause".

My issue is that trying to hold on to everything increases the risk of loss.

Since I've killed this horse more than a few times now, I'll shut up!!

GLTU